Viruses with enhanced lytic potency

Details Viruses with enhanced lytic potency Viruses with enhanced lytic potency

2003-01-14

2011-11-08

Long, Scott (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S456000, C435S235100

Reexamination Certificate

active

08052965

ABSTRACT:
Described is a replication competent recombinant virus, being capable to replicate and having lytic capacity in target cells, the said cell being hampered in the p53 dependent apoptosis pathway, the virus including in the genome thereof, the coding sequence of at least one restoring factor functional in restoring the p53 apoptosis pathway in the said target cells, operably linked to one or more expression control sequences, functional in the said target cells, as well as the use thereof in the preparation of a medicament, in particular for suppressing uncontrolled cell growth.

REFERENCES:
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 6824771 (2004-11-01), Curiel et al.
patent: 2002/0187126 (2002-12-01), Blaho et al.
patent: WO 95/12660 (1995-05-01), None
patent: WO 97/30732 (1997-08-01), None
patent: WO 98/01563 (1998-01-01), None
patent: WO 98/46779 (1998-10-01), None
patent: WO 98/46781 (1998-10-01), None
patent: WO 00/29573 (2000-05-01), None
patent: WO 00/71078 (2000-11-01), None
patent: WO 01/05437 (2001-01-01), None
patent: WO 01/44280 (2001-06-01), None
patent: WO 01/74403 (2001-10-01), None
Debbas and White, Genes Dev. 1993, 7:546-54.
Querido et al. Genes and Dev. 2001. 15:3104-3117.
Fueyo et al. Oncogene 2000. 19:2-12.
Nevins. Human Molecular Genetics. 2001. 10(7):699-703.
Bressac et al. 1990. PNAS 87:1973-1977.
Lin et al. Cancer Research 60, 5895-5901, Oct. 15, 2000.
Moore et al. PNAS. 1996. p. 11295-11301.
Hallenbeck et al (Human Gene Therapy. 1999; 10:1721-1733).
Of Xu et al. (Human Gene Therapy. 1997; 8:177-185).
V.W. Van Beusechem, P.B. Van Den Doel, W.R. Gerritsen, Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human concer cell overexpressing murine double minute 2, Mol Cancer Ther 2005;4(6). Jun. 2005, pp. 1013-1018.
Querido E. et al., Accumulation of P53 Induced by the Adenovirus E1A Protein Requires Regions Involved in the Stimulation of DNS Synthesis, Journal of Virology, The American Society for Microbiology, US, vol. 71, No. 5, May 1997, pp. 3526-3533.
P.Yew, X. Liu, A. Berk, Adenovirus E1B Oncoprotein Tethers a Transcriptional Repression Domain to p53, Genes and Development, Cold Spring Harbor, NY, US, vol. 8 No. 2, 1994, pp. 190-202.
Teodoro J G et al, Adenovirus E1A Proteins induce apoptosis by Both P53-dependent and P53-independent mechanisms, Oncogene, Basingstoke, Hants, GB, vol. 11, No. 3, Aug. 3, 1995, pp. 467-474.
Querido et al., Regulation of P53 Levels by the E1B 55—Kilodalton protein and E4orf6 in Adenovirus-Infected Cells, Journal of Virology, the American Society for Microbiology, US, vol. 71, No. 5, May 1, 1997, pp. 3788-3798.
Tsunoda H. et al., Effects of Wild-Type and Mutated P53 and ID Proteins on the Induction of Apoptosis by Adenovirus E1A, c-Myc, Bax and Nip3 in p53 Null Mouse Cerebellum Cells, Biochemical and BiophysicalResearch Communicationsm Academic Press Inc, Orlando, FL, US vol. 255, No. 3, 1999, pp. 722-730.
Beusechem et al., Conditionally Replicative Adenovirus Expressing p53 Exhibits Enhanced Oncolytic Potency, Cancer Research, vol. 62, pp. 6165-6171, Nov. 1, 2002.
Turnell et al., “The Replicative Capacities of Large E1B-Null Group A and Group C Adenoviruses are Independent of Host Cell p53 Status”, Journal of Virology, vol. 73, No. 3, pp. 2074-2083 (1999).ell p53 Status, Journal of Virology, vol. 73, No. 3, pp. 2074-2083 (1999).
Goodrum et al. “p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection”, Journal of Virology, vol. 72, No. 12, pp. 9479-9490 (1998).
Ridgway et al., “p53/E1b58kDa Complex Regulates Adenovirus Replication”, Journal of Virology, vol. 237, pp. 404-413 (1997).
Dix et al., “Efficient Induction of Cell Death by Adenoviruses Requires Binding of E1B55k and p53”, Cancer Research, vol. 60, pp. 2666-2672, (2000).
Hermiston et al., “Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes,” Cancer Gene Therapy (2002) 9, 1022-1035.

Affiliated with

Also associated with

Rating

Viruses with enhanced lytic potency does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viruses with enhanced lytic potency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viruses with enhanced lytic potency will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4303039